- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
IQVIA’s Doug Long: Adalimumab Biosimilars Provide More Opportunity for Price Discounts
The impact that the adalimumab biosimilars will have in 2023 is going to depend on when they all get to market, said Doug Long, MBA, vice president, industry relations, IQVIA.
The impact that the adalimumab biosimilars will have in 2023 is going to depend on when they all get to market, said Doug Long, MBA, vice president, industry relations, IQVIA.
Transcript
There are at least 7 adalimumab biosimilars expected to come to market in the United States in 2023. What impact do you think they might have in the short and long term?
Well, a lot depends on how much the originator protects the franchise. And, usually, they protect the franchise with either rebates or they cut the price. But nevertheless, is that the cost of autoimmune drugs are going to go down, because of what the manufacturers do and what the biosimilar manufacturers do. And again, it depends.
I think Amgen has 5 months' exclusivity or something like that. So, it depends on when they all hit. So, the more competition there is, the more chance there is for, you know, price discounting.
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
An Elevated Member Experience, More Education, and Martha Stewart at the AAD 2025 Annual Meeting
March 4th 2025Seemal R Desai, MD, FAAD, president of the American Academy of Dermatology (AAD), emphasized his commitment to enhancing the upcoming 2025 annual meeting by introducing new events and expanding educational offerings to better serve and engage members.
Read More
